Answers are grounded in this paper and cite their sources.
Observational analysis shows NRCAM affects patient survival in lower-grade gliomas, suggesting its role as a biomarker.
NRCAM is recurrently dysregulated in lower-grade gliomas through CNVs and DNA methylation, both of which stratify patient survival. Together with previously reported splicing deregulation, these data suggest that NRCAM functions as a multilayered regulator of glioma progression. NRCAM methylation may represent a potential prognostic biomarker, while therapeutic modulation of NRCAM warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Lehrer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: